In collaboration with the healthcare sector to control diseases, many domestic pharmaceutical companies are proactively investing, enhancing production capacity, and diversifying their product portfolios. Among them is Imexpharm, a company with a focus on investing in R&D and international-standard production systems.

The company currently operates 12 EU-GMP production lines across three EU-GMP certified factory complexes, providing a foundation for producing a wide range of high-quality medications to meet treatment needs from central to local hospitals.

Research and development activities at Imexpharm's EU-GMP certified pharmaceutical factory. Photo: Imexpharm

Research and development activities at Imexpharm's EU-GMP certified pharmaceutical factory. Photo: Imexpharm

Imexpharm's antibiotic portfolio covers various essential treatment groups, focusing on active ingredients recommended in treatment guidelines and new active substances. These groups include Amoxicillin combined with Clavulanic Acid, available in both oral and injectable forms; Avibactam, which contributes to treating multi-drug resistant strains; Colistin, a choice solution for difficult-to-treat Gram-negative infections; and the Quinolone group, which plays an important role in treating respiratory and urinary tract infections.

According to a representative from Imexpharm, the company utilizes antibiotic raw materials produced through Enzymatic technology, replacing most solvents and chemicals used in traditional manufacturing processes. This ensures the purity and safety of their products. The company also conducts research to ensure optimal application of each antibiotic subgroup according to disease stratification, from simple respiratory infections in the community to severe and complex cases in hospitals or ICUs. They also stay updated on new treatment recommendations, given the increasing antibiotic resistance of bacteria.

Imexpharm is developing a diverse range of anti-infective drugs for various disease groups. In addition, the company is expanding its non-antibiotic product portfolio, from chronic disease medications to health support products, to address Vietnam's rapidly changing epidemiological trends.

Master Le Nu Minh Hoai, Deputy General Director of Business at Imexpharm, delivers the opening speech at the Imexforum in Ho Chi Minh City on 5/7. Photo: Imexpharm

Master Le Nu Minh Hoai, Deputy General Director of Business at Imexpharm, delivers the opening speech at the Imexforum in Ho Chi Minh City on 5/7. Photo: Imexpharm

As part of its commitment to connecting science with the community, Imexpharm organized the Imexforum 2025, focusing on "Advances in respiratory infection diagnostics and rational antibiotic use in community-acquired and hospital-acquired respiratory infections." The series of events took place in Ho Chi Minh City, Da Nang, and Hanoi from 21/6 to 23/8, with the participation of leading experts to share the latest advancements in diagnosing and treating respiratory infections.

Discussion session with speakers at the Imexforum in Hanoi on 23/8. Photo: Imexpharm

Discussion session with speakers at the Imexforum in Hanoi on 23/8. Photo: Imexpharm

The Ministry of Health recognizes that infectious diseases remain a significant concern for Vietnam's healthcare sector in 2025. This stems from the country's tropical monsoon climate, high population density, and increasing factors such as climate change and environmental pollution, which significantly impact the host-pathogen-vector cycle.

Gastrointestinal and respiratory infections, as well as mosquito-borne diseases, are projected to increase, especially during the peak summer travel season of 2025 when travel demand surges. In recent months, several hospitals in Ho Chi Minh City have reported a surge in dengue fever cases.

From seasonal diseases like influenza, dengue fever, and hand, foot, and mouth disease to emerging diseases, the rapid spread and high infection rates pose significant challenges to the healthcare system. Many dengue fever patients face the risk of secondary infections. Meanwhile, in northern Vietnam, cases of pneumonia among children and the elderly are on the rise, leading to overcrowding in some provincial hospitals.

Statistics from the Ministry of Health reveal that infectious diseases like dengue fever, measles, avian influenza A(H5N1), and monkeypox continued to be complex in 2025. In 2024, the country recorded over 141,000 dengue fever cases, including 28 deaths; over 76,000 hand, foot, and mouth disease cases; 287,548 seasonal flu cases; and 38,364 suspected measles cases.

Aligned with the Ministry of Health's 2025 goal of promptly and effectively controlling infectious diseases and minimizing morbidity and mortality, while remaining prepared for pandemics or emergencies, a representative from Imexpharm emphasized, "This is both the responsibility of the healthcare system and the shared duty of pharmaceutical companies to provide healthcare solutions for the community."

The Dan